Strategy of Intracoronary Imaging Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels (STENTLESS II)
Strategies of Intracoronary Imaging Guided Drug-coated Balloons (DCB) Versus Angiography Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels Trial (STENTLESS II)
A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Erli Zhang
- 電話番号:+86 18500853301
- メール:zhangerli@fuwaihospital.org
研究場所
-
-
-
Beijing、中国、100037
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Participants must meet all of the following three criteria:
- Age ≥18 years;
- De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm;
- One or more trial target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment with DCB.
Exclusion Criteria:
Participants who meet any of the following conditions are not eligible for inclusion:
- Patients with hemodynamically unstable acute coronary syndrome
- Previous percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) on the target vessel within 12 months
- In-stent restenosis requiring revascularization
- Complex Coronary Bifurcation Lesions*
- Lesions with any of the following anatomical characteristics are presumably not suitable for DCB treatment:
1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a life expectancy of less than 1 year. 8. Known contraindication to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Intracoronary imaging-Guided Drug-coated balloon strategy
DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria. |
In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed. |
|
アクティブコンパレータ:CAG-guided Drug-coated balloon strategy
In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment. |
For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Target vessel failure
時間枠:12 months
|
Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization |
12 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Device success
時間枠:0 day (during index PCI)
|
|
0 day (during index PCI)
|
|
Procedure success
時間枠:7 days
|
Device success Freedom from in-hospital TVF |
7 days
|
|
Periprocedural complications
時間枠:48 hours
|
Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion |
48 hours
|
|
Incidence of cardiac death
時間枠:1, 12, 24, 36, and 60 months
|
Incidence of cardiac death |
1, 12, 24, 36, and 60 months
|
|
Incidence of target-vessel myocardial infarction
時間枠:1, 12, 24, 36, and 60 months
|
Incidence of target-vessel myocardial infarction |
1, 12, 24, 36, and 60 months
|
|
Incidence of clinically indicated target vessel revascularization
時間枠:1, 12, 24, 36, and 60 months
|
Incidence of clinically indicated target vessel revascularization |
1, 12, 24, 36, and 60 months
|
|
Patient-oriented composite endpoint (PoCE)
時間枠:1, 12, 24, 36, and 60 months
|
Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization |
1, 12, 24, 36, and 60 months
|
|
all-cause mortality
時間枠:1, 12, 24, 36, and 60 months
|
all-cause mortality |
1, 12, 24, 36, and 60 months
|
|
Any myocardial infarction
時間枠:1, 12, 24, 36, and 60 months
|
Any myocardial infarction |
1, 12, 24, 36, and 60 months
|
|
Any stroke
時間枠:1, 12, 24, 36, and 60 months
|
Any stroke |
1, 12, 24, 36, and 60 months
|
|
Any revascularization
時間枠:1, 12, 24, 36, and 60 months
|
Any revascularization |
1, 12, 24, 36, and 60 months
|
|
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)
時間枠:1,12, 24, 36, and 60 months
|
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC)) |
1,12, 24, 36, and 60 months
|
|
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)
時間枠:1, 12, 24, 36, and 60 months
|
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5) |
1, 12, 24, 36, and 60 months
|
|
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
時間枠:1, 12, 24, 36 and 60 months
|
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR |
1, 12, 24, 36 and 60 months
|
|
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
時間枠:1, 12, 24, 36 and 60 months
|
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events |
1, 12, 24, 36 and 60 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- FW-ZEL-003
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.
IPD 共有時間枠
Beginning 36 months after publication of the primary study results and continuing for 5 years.
IPD 共有アクセス基準
Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。